Enzymatic Targets for Drug Discovery Against Alzheimer's Disease

Memantine and Glutamate Antagonists in the Treatment of Alzheimer's Disease: Current Updates

Author(s): Rakesh Kore, Priya Tiwari, Vijay K Patel, Ekta Shirbhate, Ravichandran Veerasamy, Achal Mishra and Harish Rajak * .

Pp: 111-120 (10)

DOI: 10.2174/9789815136142123010008

* (Excluding Mailing and Handling)


Alzheimer’s disease (AD) is the most important cause of dementia and a complex chronic neurodegenerative disease. Many of the currently marketed drugs are used to treat this disease condition, but a major issue with these drugs is their neurotoxicity. Alzheimer's treatment with the FDA approval of memantine resolves the neurotoxicity issue. Memantine acts on glutamate and its receptors in the treatment of AD. Recent studies show that NMDA receptor-acting drugs are doing well in the healing of Alzheimer's patients, because of their selectivity on receptor and neuroprotective activity. The present work is an attempt to collect updated information about memantine and glutamate antagonists used for the treatment of AD. 

Keywords: Alzheimer's Disease, Amyloid Beta Precursor Protein (APP), Central Nervous System, Glutamate, Memantine

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy